Market News & Trends
Activartis Develops Cancer Vaccine in Phase II, Seeks Partner
Activartis GmbH (formerly Trimed Biotech GmbH) recently announced it is developing a cancer immunotherapy concept that is currently in Phase II clinical trials. Initially directed…
Acton Pharmaceuticals Announces License Agreement for Nasal Aerosol
Acton Pharmaceuticals, Inc. recently announced it has completed a licensing agreement with Sanofi US for prescription NASACORT HFA (triamcinolone acetonide) Nasal Aerosol for the treatment…
Biogen Idec & Portola Pharmaceuticals Strike $553-Million Deal
Biogen Idec and Portola Pharmaceuticals, Inc. recently announced they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop…
Bio-Images & Medimetrics Partner to Deliver Next-Generation Smart Pill Technology
Bio-Images Research and Medimetrics Personalized Drug Delivery recently announced a partnership to introduce the IntelliCap to the global pharmaceutical industry as a clinical research tool.…
Encap Drug Delivery & Lena Nanoceutics to Develop Nano-Capsule Technology
Encap Drug Delivery and Lena Nanoceutics recently announced a collaboration agreement to develop a new drug delivery technology (Nano-Capsules) that combines Lena's proprietary nanoparticle engineering…
Hovione Launches Rapid Proof-of-Concept DPI Product Development Service
Hovione recently announced the launch of its Rapid Proof-of-Concept Study for the development of dry powder inhalation (DPI) products. Building on Hovione's well-established DPI development…
Imagen Biotech Banks $40 Million to Advance Ophthalmology Therapies
Imagen Biotech, Inc. recently announced it has secured up to $40 million in Series A financing from SV Life Sciences, Novo Ventures, and Fidelity Biosciences…
Patheon Signs 3-Year $18-Million Development Agreement
Patheon, Inc., a global provider of drug development and manufacturing services to the international pharmaceutical industry, recently announced that Boehringer Ingelheim, a leading globally operating…
10/25/2011
Abbott to Separate Into Two Leading Companies Abbott recently announced it plans to separate into two publicly traded companies, one in diversified medical products, and…
Abbott to Separate Into Two Leading Companies
Abbott recently announced it plans to separate into two publicly traded companies, one in diversified medical products, and the other in research-based pharmaceuticals. The diversified…
Evonik Launches EUDRAGIT E PO ReadyMix
Essen, Germany-based Evonik Industries recently announced it has launched EUDRAGIT E PO ReadyMix, a ready-to-use powder blend for taste-masking and moisture protection coatings of pharmaceutical…
Halozyme Announces Positive Results From Roche's Phase III Trial
Halozyme Therapeutics, Inc. recently announced that the Phase III HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a…
10/17/2011
Oncobiologics Announces Two New Agreements Worth Almost $80 Million Oncobiologics recently announced it has signed two major agreements. The first is with Parilis Biopharmaceuticals, an…
Biostar Pharmaceuticals Signs Agreement to Acquire Shaanxi Weinan Huaren
Biostar Pharmaceuticals, Inc. recently announced that its wholly owned subsidiary, Shaanxi Aoxing Pharmaceutical, Ltd., entered into a Share Transfer Agreement to acquire Shaanxi Weinan Huaren…
DNAnexus Secures $15-Million Funding Led by Google Inc. Ventures & TPG Biotech
DNAnexus, a DNA data management and analysis platform, recently announced it has secured $15 million in second-round funding, led by Google Ventures and TPG Biotech.…
Eagle Pharmaceuticals & Flamel Technologies Announce License & Development Agreement
Flamel Technologies SA and Eagle Pharmaceuticals, Inc. recently announced that the two companies have entered into a license and development agreement for a Medusa-based hydrogel…
Emisphere Reports First Interpretable Results on Second Phase III Study
On July 23, 2010, Emisphere Technologies, Inc. reported that Novartis Pharma AG and its license partner Nordic Bioscience A/S provided certain information in connection with…
GlycoMimetics, Inc. Inks Licensing Deal Worth Up to $340 Million With Pfizer
GlycoMimetics, Inc. recently announced it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. for the GlycoMimetics investigational compound GMI-1070. GMI-1070 is a…
Oncobiologics Announces Two New Agreements Worth Almost $80 Million
Oncobiologics recently announced it has signed two major agreements. The first is with Parilis Biopharmaceuticals, an early stage biotech company, and involves worldwide licensing for…
Zosano Pharma & Asahi Kasei Pharma Enter Agreement for Transdermal Patch for Up to $132.5 Million
Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation (AKP) recently announced they have entered into a long-term strategic collaboration for the development, commercialization, and supply…
